NAS:TPTX (USA)
Turning Point Therapeutics Inc $ 111.68 -5.25 (-4.49%)
Volume:
311,423
Avg Vol (1m):
260,333
Market Cap $:
5.38 Bil
Enterprise Value $:
4.67 Bil
PE Ratio:
0.00
PB Ratio:
6.72
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 171.67 | ||
| Equity-to-Asset | 0.97 | ||
| Debt-to-Equity | 0.01 | ||
| Debt-to-EBITDA | -0.03 | ||
| Altman Z-Score | 146.8 | ||
| Beneish M-Score | 0 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -547.85 | ||
| Net Margin % | -523.5 | ||
| ROE % | -24.99 | ||
| ROA % | -24.19 | ||
| ROC (Joel Greenblatt) % | -2033.04 |
TPTX
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 6.72 | ||
| PS Ratio | 188.33 | ||
| EV-to-EBIT | -34.13 | ||
| EV-to-EBITDA | -34.71 | ||
| EV-to-Revenue | 186.91 | ||
| Current Ratio | 35.45 | ||
| Quick Ratio | 35.45 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History |
|---|
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.72 | ||
| Earnings Yield (Greenblatt) % | -2.92 |